Medical Devices; Radiology Devices; Classification of the Fludeoxyglucose F18-Guided Radiation Therapy System
FDA classifies fludeoxyglucose F18-guided radiation therapy systems as class II medical devices with special controls, imposing new regulatory requirements on manufacturers.
Aforeworn detected this change in the Healthcare AI Regulation (FDA / ONC) space on August 6, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated Medium urgency. Manufacturers of fludeoxyglucose F18-guided radiation therapy systems, including health tech startups and medical device companies in the radiation oncology space. should confirm how it applies to their specific situation before acting. There is a time constraint attached: Not specified in the excerpt; likely effective upon publication in the Federal Register (August 6, 2026).. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Healthcare AI Regulation (FDA / ONC) continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.
What changed
The FDA has formally classified these systems as class II devices, meaning they now require 510(k) premarket notification and must comply with special controls (details not specified in the excerpt).
Who it affects
Manufacturers of fludeoxyglucose F18-guided radiation therapy systems, including health tech startups and medical device companies in the radiation oncology space.
What you must do
Manufacturers must review the full classification document to understand the special controls and ensure their devices meet the new requirements before marketing.
Deadline
Not specified in the excerpt; likely effective upon publication in the Federal Register (August 6, 2026).
Never miss a change like this again
Aforeworn watches Healthcare AI Regulation (FDA / ONC) around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.
Start your free trial